Tirzepatide vs Semaglutide: Which GLP-1 Wins on the Data?

Tirzepatide and semaglutide are the two most prescribed injectable weight loss medications in the United States. They share a drug class, a once-weekly injection schedule and a similar side effect profile dominated by nausea and GI complaints. But they are not the same molecule, and the clinical data shows a measurable gap in efficacy. This page breaks down the pharmacology, the head-to-head trial results, brand-name pricing and compounded alternatives so you can discuss the right option with your physician.

How Tirzepatide and Semaglutide Work Differently

Both drugs belong to the incretin class. They mimic gut hormones that signal fullness after eating, slow gastric emptying and regulate blood sugar. The difference is in how many receptors each drug targets. Semaglutide activates one. Tirzepatide activates two.

Dual GIP/GLP-1 Agonist vs GLP-1 Only

Semaglutide binds the GLP-1 receptor exclusively. That receptor is found in the pancreas, stomach, intestine and brain. Activation suppresses appetite, delays stomach emptying and improves insulin secretion. The mechanism is well established. Semaglutide received FDA approval for type 2 diabetes as Ozempic in 2017 and for weight management as Wegovy in 2021.

Tirzepatide adds a second target. Along with GLP-1 receptor activation, it binds glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP receptors are expressed in adipose tissue, pancreatic beta cells and the central nervous system. Preclinical data suggests GIP receptor activation improves fat metabolism and enhances insulin sensitivity through pathways that are partially independent of GLP-1 signaling. The clinical translation of this dual mechanism is straightforward: larger average weight loss.

Whether the GIP component explains the entire efficacy difference or whether other pharmacokinetic factors contribute is still debated in the literature. The practical result is that tirzepatide consistently produces larger weight reductions across every published trial comparing the two drugs. For more on tirzepatide dose-response data, see our effectiveness page.

SURMOUNT-5 Head-to-Head Trial Results

Until SURMOUNT-5, the comparison between tirzepatide and semaglutide relied on cross-trial analysis. Different patient populations, different baseline weights and different trial designs made direct comparison imprecise. SURMOUNT-5 eliminated that limitation by randomizing the same patient group to either drug and measuring outcomes over 72 weeks (PMID 40353578).

Weight Loss Outcomes

Participants on tirzepatide lost an average of 20.2% of their body weight. Those on semaglutide lost 13.7%. The 6.5 percentage point difference was statistically significant and clinically meaningful. For a 220-pound individual, that gap translates to roughly 14 additional pounds lost with tirzepatide over the same treatment period.

The tirzepatide result in SURMOUNT-5 is consistent with SURMOUNT-1, where the 15 mg dose produced 20.9% weight loss at 72 weeks (PMID 35658024). The semaglutide arm's 13.7% also aligns with semaglutide's published performance in the STEP trials. Neither drug underperformed its historical data. Tirzepatide simply does more.

Side Effect Comparison

Both drugs cause gastrointestinal adverse events at high rates. The side effect profiles are similar in kind because both slow gastric emptying and act on overlapping central appetite circuits. The differences in frequency are modest.

These frequencies come from the respective FDA prescribing labels (Zepbound for tirzepatide, Wegovy for semaglutide). Both drugs carry the same boxed warning regarding thyroid C-cell tumors observed in rodent studies. Both are contraindicated in patients with medullary thyroid carcinoma or MEN2. Both list pancreatitis and gallbladder events among serious risks. Our tirzepatide side effects page covers the safety profile in more detail.

Brand-Name Options Compared

There are four brand-name products between these two molecules. Each has a different FDA-approved indication, even though the active ingredients overlap. The table below clarifies what each brand is actually approved for.

A common misconception: Ozempic is not approved for weight loss. It is approved for type 2 diabetes only. Wegovy is the semaglutide product approved for chronic weight management at a higher dose (2.4 mg vs 2 mg). Similarly, Mounjaro is a diabetes drug. Zepbound is the weight management version of tirzepatide. Prescribers sometimes use Mounjaro or Ozempic off-label for weight loss, but insurance coverage for off-label use is inconsistent.

Compounded Versions Compared

Both tirzepatide and semaglutide are available through compounding pharmacies at substantially lower prices than the brand-name products. Compounded versions are prescribed by licensed providers and dispensed by licensed pharmacies, but they have not undergone the FDA approval process.

Compounded Tirzepatide Providers

Two providers we track offer compounded tirzepatide. BiltRx charges a flat $129 per month through a US 503A compounding pharmacy and includes an online medical consultation. Arc-1 prices tirzepatide with added glycine and B12 at $199.99 (2.5 mg), $249.99 (5 mg) and $399.99 (7.5 mg), with free shipping and a 30-day guarantee. Arc-1 is LegitScript certified but unavailable in CA, AR, IN, MN and SC. See our BiltRx vs Arc-1 comparison for a detailed breakdown.

Compounded Semaglutide Providers

BiltRx also offers compounded semaglutide at $81 per month, making it the least expensive injectable GLP-1 option currently available through the providers we track. The semaglutide formulation is dispensed through the same 503A pharmacy network as their tirzepatide product.

The cost gap is the reason most patients consider compounded versions. For a patient paying out of pocket, choosing compounded tirzepatide from BiltRx over brand-name Zepbound saves roughly $16,440 per year. That figure assumes no insurance coverage and no manufacturer coupons for the brand-name product. Our compounded vs brand-name comparison covers the trade-offs in detail.

Which One Should You Ask Your Doctor About?

The trial data favors tirzepatide on efficacy. SURMOUNT-5 showed a 6.5 percentage point advantage over semaglutide in a head-to-head setting. That is not a trivial margin. For patients whose primary goal is maximum weight reduction, tirzepatide has the stronger evidence base.

Semaglutide has a longer post-marketing track record. It has been on the market since 2017 and has published cardiovascular outcome data from the SELECT trial. For patients with established cardiovascular disease or those whose insurers cover semaglutide but not tirzepatide, it remains a reasonable choice.

Cost may override efficacy for many patients. Compounded semaglutide at $81 per month is cheaper than compounded tirzepatide at $129. For patients who respond well to semaglutide and tolerate it without issues, the lower price might outweigh the incremental weight loss benefit of switching.

The decision involves trade-offs between efficacy, safety profile, insurance coverage, out-of-pocket cost and individual tolerance. A physician familiar with your medical history is the right person to weigh those factors. If cost is a barrier to either brand-name product, ask about compounded options and whether they are appropriate for your situation.